Form 4: Third Harmonic Bio, Inc. Executive Granted Stock Options

Christopher Dinsmore, Chief Scientific Officer of Third Harmonic Bio, Inc., was granted stock options for 210,000 shares on May 16, 2024.

Summary

• Christopher Dinsmore, the Chief Scientific Officer of Third Harmonic Bio, Inc., received an employee stock option on May 16, 2024.
• The option grants him the right to buy 210,000 shares of common stock at an exercise price of $14.23.
• The options vest over time, with 25% vesting on May 16, 2025, and the remainder vesting monthly until fully vested, contingent upon continued service.
• The expiration date for the options is May 15, 2034.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a routine disclosure of executive compensation. The grant itself is a positive for the executive, but doesn't necessarily indicate a positive or negative outlook for the company.

Positives

• The granting of stock options to the Chief Scientific Officer aligns his interests with those of the shareholders.
• The vesting schedule incentivizes continued service and contribution to the company's success.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's future performance.

Industry Context

Stock option grants are a common practice in the biotechnology industry to attract and retain key personnel, aligning their interests with the long-term success of the company.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for executives in biotech companies.
• The size of the grant (210,000 shares) would need to be compared to grants at peer companies of similar market capitalization and stage of development to assess its relative value.
• Vesting schedules are also typical, with back-ended vesting to encourage long-term commitment.

Stakeholder Impact

• The stock option grant could have a minor dilutive effect on existing shareholders.
• The grant incentivizes the Chief Scientific Officer to contribute to the company's success, which could benefit all stakeholders.

Key Dates